Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials

Abstract

We compared the ability of the Kurtzke Expanded Disability Status Scale (EDSS) and a composite outcome of non-physician-based measures of time to ambulate 25 feet (TA) and manual dexterity (the Box and Block Test [BBT], and 9-Hole Peg Test [9HPT]) to discriminate treatment effects in the Phase III study of interferon beta-1a. A log-rank comparison of Kaplan-Meier curves by treatment group showed the non-physicianbased composite of BBT, 9HPT, and TA was of comparable sensitivity (P=0.013) in discriminating sustained treatment failure as the EDSS alone (P=0.029). The composite of BBT, 9HPT, TA, and EDSS was more sensitive (P=0.009) in discriminating sustained treatment failure than the EDSS alone. Compositive outcomes of the EDSS and non-physician-based measures of manual dexterity and timed ambulation provide an appealing strategy to reduce the number of patients required to discriminate treatment effects in MS clinical trials.

Keywords

multiple sclerosis clinical trials outcome measures

Get full access to this article

View all access options for this article.

References

Jacobs LD , et al. and The Multiple Sclerosis Research Group (MSCRG) (1996) Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis . Ann Neurol 39: 285-294 .

Jacobs LD , et al. and The Multiple Sclerosis Research Group (MSCRG) (1995) A Phase III trial of intramuscular recombinant beta interferon as treatment for exacerbation-remitting multiple sclerosis: design and conduct of study; baseline characteristics of patients . Multiple Sclerosis 1: 118-135 .

Kurtzke JF , (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 33: 1444-1452 .

Weinschenker BG (1996) Clinical Outcome Measures for Multiple Sclerosis. In Multiple Sclerosis: advances in clinical trial design, treatment and future perspectives. Eds; Goodkin DE , Rudick RA. Springer-Verlag, London . pp 105-122.

Goodkin DE , et al. (1992) Inter- and intra-rater scoring agreement using grade 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS) . Neurology 42: 859-863 .

Mathiowetz V , Volland G , Kashman N , Weber K. (1985) Adult norms for box and block test of manual dexterity . Occup Ther J Res 39: 386-391 .

Mathiowetz V , Weber K , Kashman N , Volland G. (1985) Adult norms for Nine Hole Peg Test of finger dexterity . Occup Ther J Res 5: 24-38 .

Goodkin DE Hertsgaard D , Seminary J (1988) Upper extremity function in multiple sclerosis: improving assessment sensitivity with Box-and-Block and Nine-Hole Peg Tests . Arch Phys Med Rehab 69: 850-854 .

Goodkin DE , et al. (1995) Low-dose (7.5 mg) oral methotrexate is effective in reducing the rate of progression of neurological impairment in patients with chronic progressive multiple sclerosis . Ann Neurol 37: 30-40 .

10.

Kaplan EL , Meier P. (1958) Nonparametric estimation from incomplete observations . J Am Stat Assoc 53: 457-481 .

11.

Cox DR , (1972) Regression models and life-tables (with discussion) . J Royal Statistical Society, Series B 34: 187-220 .

12.

Goodkin DE , et al. (1995) Low-dose (7.5 mg) oral methotrexate is effective in reducing the rate of progresion of neurological impairment in patients with chronic progressive multiple sclerosis . Ann Neurol 37: 30-40 .

13.

Goodkin DE , et al. (1996) Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs . Neurology 47: 1153-1157 .

14.

Fischer JS , et al. (1994) Low-dose (7.5 mg) oral methotrexate improves neuropsychological function in patients with chronic progressive MS . Ann Neurol 36: 289-289 .

15.

Fisher JS , et al. (1997) Neuropsychological outcomes in the clinical trial of methotrexate in chronic progressive multiple sclerosis: traditional pre-post analyses may fail to tell the tail . Journal of the International Neuropsychological Society 3: 35-35 .